The Impact of Smoking on Recurrence and Progression of Non-muscle Invasive Bladder Cancer: a Systematic Review and Meta-analysis

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2022 Nov 20

PMID 36404390

Authors

Aleksander Slusarczyk

Piotr Zapala

Lukasz Zapala

Piotr Radziszewski

Affiliations

Soon will be listed here.

Abstract

Objectives: Although smoking is a well-recognized causative factor of urothelial bladder cancer and accounts for 50% of cases, less is known about the prognostic significance of smoking on non-muscle invasive bladder cancer (NMIBC) prognosis. This systematic review and meta-analysis aimed to evaluate the effect of smoking on the risk of NMIBC recurrence and progression.

Materials And Methods: We systematically searched Medline, Web of Science and Scopus databases for original articles published before October 2021 regarding the effect of smoking on NMIBC recurrence and progression. Information about smoking status and the number of events or odds ratio or hazard ratio for event-free survival must have been reported to include the study in the analysis. Quality In Prognosis Studies tool was utilized for the risk of bias assessment.

Results: We selected 64 eligible studies, including 28 617 patients with NMIBC with available data on smoking status. In a meta-analysis of 28 studies with 7885 patients, we found that smokers (current/former) were at higher risk for recurrence (OR = 1.68; 95% CI 1.34-2.09; P < 0.0001) compared to never smokers. Subgroup analysis of 2967 patients revealed that current smokers were at a 1.24 higher risk of recurrence (OR = 1.24; 95% CI 1.02-1.50; P = 0.03) compared to former smokers. A meta-analysis of the hazard ratio revealed that smokers are at higher risk of recurrence (HR = 1.31; 95%CI 1.15-1.48; P < 0.0001) and progression (HR = 1.18; 95%CI 1.08-1.29; P < 0.001) compared to never smokers. Detrimental prognostic effect of smoking on progression, but not for recurrence risk was also noted in the subgroup analysis of high-risk patients (HR = 1.30; 95%CI 1.09-1.55; P = 0.004) and BCG-treated ones (HR = 1.15; 95%CI 1.06-1.25; P < 0.001).

Conclusion: In conclusion, patients with non-muscle invasive bladder cancer and a history of smoking have a worse prognosis regarding recurrence-free and progression-free survival compared to non-smokers.

Citing Articles

Perioperative Intensive Smoking Cessation Intervention Among Smokers Who Underwent Transurethral Resection of Bladder Tumor (TURBT) in Two Different Settings: A Randomized Controlled Trial.

Lydom L, Lauridsen S, Liljendahl M, Schmedes A, Joensen U, Tonnesen H Cancers (Basel). 2025; 17(4).

PMID: 40002306 PMC: 11853449. DOI: 10.3390/cancers17040713.

The Potential for Lifestyle Intervention Among Patients Undergoing Transurethral Resection of Bladder Tumour Based on Patient Needs Including Smoking and Other Risky Lifestyle Factors: A Cross-Sectional Study.

Lydom L, Lauridsen S, Joensen U, Tonnesen H Int J Environ Res Public Health. 2025; 21(12.

PMID: 39767473 PMC: 11675626. DOI: 10.3390/ijerph21121633.

Smoking behavior and the risks of tumor recurrence and progression in patients with non-muscle-invasive bladder cancer.

Kiebach J, Beeren I, Aben K, Witjes J, van der Heijden A, Kiemeney L Int J Cancer. 2024; 156(8):1529-1540.

PMID: 39499231 PMC: 11826114. DOI: 10.1002/ijc.35250.

Deciphering the molecular heterogeneity of intermediate- and (very-)high-risk non-muscle-invasive bladder cancer using multi-layered studies.

Akand M, Jatsenko T, Muilwijk T, Gevaert T, Joniau S, Van der Aa F Front Oncol. 2024; 14:1424293.

PMID: 39497708 PMC: 11532112. DOI: 10.3389/fonc.2024.1424293.

Rapid Lifestyle Recommendations to Improve Urologic, Heart and Overall Health.

Moyad M Curr Urol Rep. 2024; 26(1):10.

PMID: 39377857 DOI: 10.1007/s11934-024-01246-0.

References

van Osch F, Jochems S, Reulen R, Pirrie S, Nekeman D, Wesselius A . The association between smoking cessation before and after diagnosis and non-muscle-invasive bladder cancer recurrence: a prospective cohort study. Cancer Causes Control. 2018; 29(7):675-683. PMC: 5999150. DOI: 10.1007/s10552-018-1046-8. View

Holz S, Albisinni S, Gilsoul J, Pirson M, Duthie V, Quackels T . Risk factor assessment in high-risk, bacillus Calmette-Guérin-treated, non-muscle-invasive bladder cancer. Res Rep Urol. 2017; 9:195-202. PMC: 5628686. DOI: 10.2147/RRU.S143865. View

Pastore A, Palleschi G, Fuschi A, Silvestri L, Al Salhi Y, Costantini E . Can daily intake of aspirin and/or statins influence the behavior of non-muscle invasive bladder cancer? A retrospective study on a cohort of patients undergoing transurethral bladder resection. BMC Cancer. 2015; 15:120. PMC: 4369111. DOI: 10.1186/s12885-015-1152-x. View

Kobayashi H, Kikuchi E, Mikami S, Maeda T, Tanaka N, Miyajima A . Long term follow-up in patients with initially diagnosed low grade Ta non-muscle invasive bladder tumors: tumor recurrence and worsening progression. BMC Urol. 2014; 14:5. PMC: 3913327. DOI: 10.1186/1471-2490-14-5. View

Cao J, Xu R, Zhao X, Zhong Z, Zhang L, Zhu X . Areca Nut Chewing and an Impaired Estimated Glomerular Filtration Rate as Significant Risk Factors for Non-Muscle-Invasive Bladder Cancer Recurrence. Sci Rep. 2016; 6:29466. PMC: 4935873. DOI: 10.1038/srep29466. View

Mitrakas L, Gravas S, Papandreou C, Koukoulis G, Karasavvidou F, Dimakopoulos G . Primary High-Grade Non-Muscle-Invasive Bladder Cancer: High NFκB Expression in Tumor Specimens Distinguishes Patients Who are at Risk for Disease Progression. Pathol Oncol Res. 2017; 25(1):225-231. DOI: 10.1007/s12253-017-0340-1. View

Andrade D, Moretti T, Azal Neto W, Benedetti J, Reis L . Smoke load prognostic impact on bacillus Calmette-Guérin (BCG) treated non-muscle invasive bladder cancer. Int Urol Nephrol. 2020; 52(8):1471-1476. DOI: 10.1007/s11255-020-02438-6. View

Serretta V, Di Maida F, Baiamonte D, Vella M, Pavone C, Cacciatore L . Does Smoking Cessation at Primary Diagnosis Reduce the Recurrence Risk of Nonmuscle-Invasive Bladder Cancer? Results of a Prospective Study. Urol Int. 2020; 104(5-6):396-401. DOI: 10.1159/000507122. View

Lammers R, Witjes W, Hendricksen K, Caris C, Janzing-Pastors M, Witjes J . Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer. Eur Urol. 2011; 60(4):713-20. DOI: 10.1016/j.eururo.2011.07.010. View

10.

Sfakianos J, Shariat S, Favaretto R, Rioja J, Herr H . Impact of smoking on outcomes after intravesical bacillus Calmette-Guérin therapy for urothelial carcinoma not invading muscle of the bladder. BJU Int. 2010; 108(4):526-30. DOI: 10.1111/j.1464-410X.2010.09874.x. View

11.

Pietzak E, Malkowicz S . Does quantification of smoking history correlate with initial bladder tumor grade and stage?. Curr Urol Rep. 2014; 15(7):416. DOI: 10.1007/s11934-014-0416-3. View

12.

Ogihara K, Kikuchi E, Yuge K, Yanai Y, Matsumoto K, Miyajima A . The Preoperative Neutrophil-to-lymphocyte Ratio is a Novel Biomarker for Predicting Worse Clinical Outcomes in Non-muscle Invasive Bladder Cancer Patients with a Previous History of Smoking. Ann Surg Oncol. 2016; 23(Suppl 5):1039-1047. DOI: 10.1245/s10434-016-5578-4. View

13.

Abd Elwahab K, Desky E, Eldery M, Mohammad F, Seleem M, El-Babouly I . Apparent Diffusion Coefficient Value can Predict Poor Bacillus Calmette-Guérin Responders in T1HG/NMIBC: Prospective Cohort Study. Clin Genitourin Cancer. 2021; 19(4):e248-e254. DOI: 10.1016/j.clgc.2021.03.001. View

14.

Crivelli J, Xylinas E, Kluth L, Rieken M, Rink M, Shariat S . Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. Eur Urol. 2013; 65(4):742-54. DOI: 10.1016/j.eururo.2013.06.010. View

15.

Hwang E, Kim Y, Hwang I, Hwang J, Jung S, Kwon D . Impact of diabetes mellitus on recurrence and progression in patients with non-muscle invasive bladder carcinoma: a retrospective cohort study. Int J Urol. 2011; 18(11):769-76. DOI: 10.1111/j.1442-2042.2011.02845.x. View

16.

Yang Y, Liu C, Yan X, Li J, Yang X . Overnight Continuous Saline Bladder Irrigation After Resection of Bladder Tumor Does Not Improve Oncological Outcomes in Patients Who Have Received Intravesical Chemotherapy. Front Oncol. 2021; 11:638065. PMC: 7988089. DOI: 10.3389/fonc.2021.638065. View

17.

Li X, Shu K, Zhou J, Yu Q, Cui S, Liu J . Preoperative Plasma Fibrinogen and D-dimer as Prognostic Biomarkers for Non-Muscle-Invasive Bladder Cancer. Clin Genitourin Cancer. 2019; 18(1):11-19.e1. DOI: 10.1016/j.clgc.2019.10.025. View

18.

Gangawar R, Ahirwar D, Mandhani A, Mittal R . Impact of nucleotide excision repair ERCC2 and base excision repair APEX1 genes polymorphism and its association with recurrence after adjuvant BCG immunotherapy in bladder cancer patients of North India. Med Oncol. 2009; 27(2):159-66. DOI: 10.1007/s12032-009-9187-y. View

19.

Zeng J, Zhang G, Chen C, Li K, Wen Y, Zhao J . Alterations in Urobiome in Patients With Bladder Cancer and Implications for Clinical Outcome: A Single-Institution Study. Front Cell Infect Microbiol. 2021; 10:555508. PMC: 7769872. DOI: 10.3389/fcimb.2020.555508. View

20.

Svatek R, Hollenbeck B, Holmang S, Lee R, Kim S, Stenzl A . The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol. 2014; 66(2):253-62. DOI: 10.1016/j.eururo.2014.01.006. View